ICER examines fair access to insurance in the USA

3 November 2023
icer_big

Boston, USA-based non-profit the Institute for Clinical and Economic Review (ICER) has published  a report on barriers to fair access in the US insurance industry.

The third such annual report on this subject, the ICER is aiming to shine a light on prescription drug coverage policies for commercial plans, and within the Veterans Health Administration.

The ICER considered four criteria in its assessment: cost sharing to patients, clinical eligibility, step therapy policies and provider qualification restrictions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology